Get the Stockscreener App
1.41
1.44%
0.02
OS Therapies Incorporated stock is traded at $1.41, with a volume of 375.17K.
It is up +1.44% in the last 24 hours and down -20.79% over the past month.
See More
Previous Close:
$1.39
Open:
$1.38
24h Volume:
375.17K
Relative Volume:
0.37
Market Cap:
$66.00M
Revenue:
Net Income/Loss:
P/E Ratio:
-
EPS:
-
Net Cash Flow:
1W Performance:
-12.96%
1M Performance:
-20.79%
6M Performance:
+2.17%
1Y Performance:
-27.69%
1-Day Range:
$0.00
$0.00
1-Week Range:
$1.375
$1.66
52-Week Range:
$1.15
$2.25
OS Therapies Incorporated Stock (OSTX) Company Profile
Name
OS Therapies Incorporated
Sector
Industry
Phone
-
Address
-
Compare OSTX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OSTX
OS Therapies Incorporated
|
1.41 | 66.00M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
OS Therapies Incorporated Stock (OSTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-26 | Initiated | Roth Capital | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
OS Therapies Incorporated Stock (OSTX) Latest News
OS Therapies Incorporated (OSTX) Stock Price, News, Quote & History - Yahoo Finance
Rubenstein Public Relations Named Agency of Record for OS Therapies - Yahoo Finance
A dog cancer treatment could launch in the U.S. in 2027, OS Therapies hopes - Stock Titan
OSTX Stock Holds Tight Range As Traders Probe Weak Financials - StocksToTrade
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial - marketscreener.com
72.7% of treated patients survived three years, versus 45.8% in historical comparisons. - stocktitan.net
Os Therapies Incorporated (OSTX-A) Stock Price and News - The Globe and Mail
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer - marketscreener.com
OS Therapies has received over $3M in tax refunds and accrued over $7M in research tax credits. - Stock Titan
OS Therapies Incorporated (OSTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) - Yahoo Finance
Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Axalta Coating Systems (AXTA) - The Globe and Mail
OS Therapies (OSTX) Slips to $1.75 as Shares Sit Between Key LevelsHedge Fund Favorites - dars.gov.et
OS Therapies (OSTX) Slips to $1.75 as Shares Sit Between Key LevelsLeveraged ETF Flow - siam.in
The FDA has approved 29 U.K.-led cancer drugs since 2021. Now a U.K. regulator will lead OS Therapies’ review. - Stock Titan
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis - Yahoo Finance
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program - Yahoo Finance
Analysts Offer Insights on NA Companies: Waystar Holding Corp. (WAY) and OS Therapies Incorporated (OSTX) - The Globe and Mail
A bone cancer treatment gets UK regulator agreement. OS Therapies plans its next trial. - Stock Titan
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing - Yahoo Finance
Form 8K OS Therapies Inc For: 10 September By Investing.com - Investing.com UK
Analysts’ Top NA Picks: BioAge Labs, Inc. (BIOA), OS Therapies Incorporated (OSTX) - The Globe and Mail
Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Concentra Group Holdings Parent, Inc. (CON) - The Globe and Mail
Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Concentra Group Holdings Parent, Inc. (CON) - The Globe and Mail
An interim cancer-trial analysis found 71.2% three-year survival versus 45.8% in a historical group. - Stock Titan
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial - Yahoo Finance
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance - Yahoo Finance
Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Nicola Mining Inc. Unsponsored ADR (NICM) - The Globe and Mail
OS (OSTX) End-of-Day Review: Ends Lower by 2.04% at $1.44 for the Current Session; Level Position: the Price Remains Bounded by the Supplied Support and Resistance at the CloseFlat Correction - careplusvn.com
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates - newsfilecorp.com
OS Therapies Expects 3-Year Survival Data in September - Stock Titan
OS Therapies (OSTX) Edges Lower to $1.6, Holding Above Key SupportDividend Arbitrage - careplusvn.com
OS Therapies Incorporated Revenue Breakdown – AMEX:OSTX - TradingView
OS Therapies Incorporated (OSTX) Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Cash Burn and Pre-Revenue StageROA Comparison - dars.gov.et
OS Therapies (OSTX) Faces Continued Pressure as Shares Test Key SupportETF Creation Redemption - dars.gov.et
Roth MKM Initiates a Buy Rating on OS Therapies Incorporated (OSTX) - The Globe and Mail
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program - Yahoo Finance
OS Therapies Incorporated (OSTX) Gets a Buy from Lake Street - The Globe and Mail
OS Therapies Incorporated (OSTX) Gets a Buy from Lake Street - The Globe and Mail
OS Therapies Third Quarter 2026 Corporate Outlook - Yahoo Finance
OS Therapies Provides U.S. Regulatory Update - Yahoo Finance
OS Therapies Incorporated(NYSEAM:OSTX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma - Yahoo Finance
OS Therapies Releases Q1 2026 Financial Results - AlphaStreet
EDGAR Filing Documents for 0001213900-26-050211 - SEC.gov
OS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX - Business Wire
Cancer drug developer taps Guardant executive for regulator strategy - Stock Titan
OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors - Yahoo Finance
OS Therapies Incorporated (OSTX) stock price, news, quote and history - Yahoo Finance UK
OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting - Yahoo Finance
OS Therapies Incorporated Stock (OSTX) Financials Data
There is no financial data for OS Therapies Incorporated (OSTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):